Yungjin Pharm. Co., Ltd.
003520.KS
Get informed when a big investor buys or sells
+ FollowMarket Cap$189.29B
Close$
$1281.36
26.5% upside
Current Fair Value
26.5% upsideUndervalued by 26.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $189.29 Billion |
|---|---|
| Enterprise Value | $263.84 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.24 |
| Beta | 0.72 |
| Outstanding Shares | 182,892,000 |
Return
| Return on Equity | -7.26% |
|---|---|
| Return on Assets | -2.75% |
| Return on Invested Capital | -3.05% |
Valuation & Multiples
| P/E Ratio | -30.6 |
|---|---|
| PEG | 3.74 |
| Price to Sales | 0.73 |
| Price to Book Ratio | 2.15 |
| Enterprise Value to Revenue | 1.04 |
| Enterprise Value to EBIT | -57.3 |
| Enterprise Value to Net Income | -43 |
| Total Debt to Enterprise | 0.3 |
| Debt to Equity | 0.91 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Yungjin Pharm. Co., Ltd.
626 employees
CEO: GiSu Lee Yungjin Pharm. Co., Ltd. engages in the development, production, and distribution of pharmaceuticals. Its products include cephalosporin, antibiotics, drugs for the central nervous system, cardiovascular, endocrine system, urinary system...